Farzan Nima
SEC CIK 1808296 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| KROS | Keros Therapeutics, Inc. | Dir | 9,767 | — | $28.2K | 3 | 2025-06-04 | 2026-06-04 |
Most active insiders at KROS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Schneeberger Daniel | 10% | — | $95.66M |
| 2 | Pontifax (China) IV L.P. | 10% | — | $84.98M |
| 3 | Cho Esther | SVP, GC | — | $123.7K |
| 4 | Seehra Jasbir | CEO, Dir | — | $113.4K |
| 5 | Lerner Lorena Raquel | CSO | — | $100.0K |
| 6 | Regnante Keith | CFO | — | $77.5K |
| 7 | BIENAIME JEAN JACQUES | Dir | $75.8K | — |
| 8 | Knowles Julius | Dir | — | $28.2K |
| 9 | Farzan Nima | Dir | — | $28.2K |
| 10 | Seth Alpna | Dir | — | $28.1K |
Transactions 3
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-06-08 16:37 | 2026-06-04 | KROS | Keros Therapeutics, Inc. | Farzan Nima | Dir | S - Sale | $10.73 | -2,625 | 9,767 | -21% | -$28.2K |
| D | 2026-06-05 16:15 | 2026-06-03 | KROS | Keros Therapeutics, Inc. | Farzan Nima | Dir | A - Grant | $0.00 | +7,142 | 12.4K | +136% | $0 |
| D | 2025-06-06 | 2025-06-04 | KROS | Keros Therapeutics, Inc. | Farzan Nima | Dir | A - Grant | $0.00 | +5,250 | 5,250 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations